Creating artificial cells to boost the immune response against cancer
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA-IRVINE · NIH-10892996
This study is exploring a new way to help your immune system better fight cancer by creating special artificial cells that can boost the growth of cancer-fighting T cells, making it easier to develop effective treatments without needing a lot of blood samples from patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA-IRVINE (nih funded) |
| Locations | 1 site (IRVINE, UNITED STATES) |
| Trial ID | NIH-10892996 on ClinicalTrials.gov |
What this research studies
This research focuses on developing artificial antigen-presenting cells (aAPCs) that can enhance the immune system's ability to recognize and attack cancer cells. By using a microfluidic process, the team aims to create these artificial cells that can effectively stimulate the expansion of anti-tumor T cells. The goal is to optimize the preparation of these aAPCs and test their effectiveness in generating a strong immune response against tumors, both in laboratory settings and in living organisms. This innovative approach seeks to overcome the limitations of traditional methods that require extensive blood samples from patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer who are seeking new treatment options and have a strong immune response.
Not a fit: Patients who are not diagnosed with cancer or those who have conditions that severely compromise their immune system may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that provide long-lasting protection against tumors.
How similar studies have performed: Other research has shown promising results with similar approaches using artificial antigen-presenting cells, indicating potential for success in this area.
Where this research is happening
IRVINE, UNITED STATES
- UNIVERSITY OF CALIFORNIA-IRVINE — IRVINE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEE, ABRAHAM P — UNIVERSITY OF CALIFORNIA-IRVINE
- Study coordinator: LEE, ABRAHAM P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.